Christine de los Reyes

Cognoptix, Inc. develops a non-invasive and predictive eye scanning test for the early detection and diagnosis of alzheimer's disease. It offers technologies to enable non-invasive quantitative measurements of amyloid aggregates in the eye. The firm also develops combined optical scanning devices and diagnostic agents for clinical, commercial and academic research use. The company was founded by Lee E. Goldstein and Leo T. Chylack Jr in 2001 and is headquartered in Acton, MA.

Alopexx Enterprises LLC engages in investing and managing health care companies. It develops medical therapies and devices for infectious diseases, oncology, central nervous system, and orphan diseases. The firm commercializes an alternative for the treatment and prevention of staphylococcal and other bacterial infections and animal vaccines. The company was founded by Daniel R. Vlock, Deborah Ramsdell and Christine de los Reyes in 2011 and is headquartered in Concord, MA.

Cognoptix, Inc. develops a non-invasive and predictive eye scanning test for the early detection and diagnosis of alzheimer's disease. It offers technologies to enable non-invasive quantitative measurements of amyloid aggregates in the eye. The firm also develops combined optical scanning devices and diagnostic agents for clinical, commercial and academic research use. The company was founded by Lee E. Goldstein and Leo T. Chylack Jr in 2001 and is headquartered in Acton, MA.

Cognoptix, Inc. develops a non-invasive and predictive eye scanning test for the early detection and diagnosis of alzheimer's disease. It offers technologies to enable non-invasive quantitative measurements of amyloid aggregates in the eye. The firm also develops combined optical scanning devices and diagnostic agents for clinical, commercial and academic research use. The company was founded by Lee E. Goldstein and Leo T. Chylack Jr in 2001 and is headquartered in Acton, MA.

Cognoptix, Inc. develops a non-invasive and predictive eye scanning test for the early detection and diagnosis of alzheimer's disease. It offers technologies to enable non-invasive quantitative measurements of amyloid aggregates in the eye. The firm also develops combined optical scanning devices and diagnostic agents for clinical, commercial and academic research use. The company was founded by Lee E. Goldstein and Leo T. Chylack Jr in 2001 and is headquartered in Acton, MA.

Janus Biotherapeutics, Inc. is an autoimmunity therapeutics company, which develops orally available compounds for the treatment of autoimmune diseases. The company was founded by Joseph Baron and Grayson Lipford and is headquartered in Wellesley, MA.

Cognoptix, Inc. develops a non-invasive and predictive eye scanning test for the early detection and diagnosis of alzheimer's disease. It offers technologies to enable non-invasive quantitative measurements of amyloid aggregates in the eye. The firm also develops combined optical scanning devices and diagnostic agents for clinical, commercial and academic research use. The company was founded by Lee E. Goldstein and Leo T. Chylack Jr in 2001 and is headquartered in Acton, MA.

Cognoptix, Inc. develops a non-invasive and predictive eye scanning test for the early detection and diagnosis of alzheimer's disease. It offers technologies to enable non-invasive quantitative measurements of amyloid aggregates in the eye. The firm also develops combined optical scanning devices and diagnostic agents for clinical, commercial and academic research use. The company was founded by Lee E. Goldstein and Leo T. Chylack Jr in 2001 and is headquartered in Acton, MA.

Cognoptix, Inc. develops a non-invasive and predictive eye scanning test for the early detection and diagnosis of alzheimer's disease. It offers technologies to enable non-invasive quantitative measurements of amyloid aggregates in the eye. The firm also develops combined optical scanning devices and diagnostic agents for clinical, commercial and academic research use. The company was founded by Lee E. Goldstein and Leo T. Chylack Jr in 2001 and is headquartered in Acton, MA.

Cognoptix, Inc. develops a non-invasive and predictive eye scanning test for the early detection and diagnosis of alzheimer's disease. It offers technologies to enable non-invasive quantitative measurements of amyloid aggregates in the eye. The firm also develops combined optical scanning devices and diagnostic agents for clinical, commercial and academic research use. The company was founded by Lee E. Goldstein and Leo T. Chylack Jr in 2001 and is headquartered in Acton, MA.

Cognoptix, Inc. develops a non-invasive and predictive eye scanning test for the early detection and diagnosis of alzheimer's disease. It offers technologies to enable non-invasive quantitative measurements of amyloid aggregates in the eye. The firm also develops combined optical scanning devices and diagnostic agents for clinical, commercial and academic research use. The company was founded by Lee E. Goldstein and Leo T. Chylack Jr in 2001 and is headquartered in Acton, MA.

Cognoptix, Inc. develops a non-invasive and predictive eye scanning test for the early detection and diagnosis of alzheimer's disease. It offers technologies to enable non-invasive quantitative measurements of amyloid aggregates in the eye. The firm also develops combined optical scanning devices and diagnostic agents for clinical, commercial and academic research use. The company was founded by Lee E. Goldstein and Leo T. Chylack Jr in 2001 and is headquartered in Acton, MA.

Cognoptix, Inc. develops a non-invasive and predictive eye scanning test for the early detection and diagnosis of alzheimer's disease. It offers technologies to enable non-invasive quantitative measurements of amyloid aggregates in the eye. The firm also develops combined optical scanning devices and diagnostic agents for clinical, commercial and academic research use. The company was founded by Lee E. Goldstein and Leo T. Chylack Jr in 2001 and is headquartered in Acton, MA.

Alopexx Enterprises LLC engages in investing and managing health care companies. It develops medical therapies and devices for infectious diseases, oncology, central nervous system, and orphan diseases. The firm commercializes an alternative for the treatment and prevention of staphylococcal and other bacterial infections and animal vaccines. The company was founded by Daniel R. Vlock, Deborah Ramsdell and Christine de los Reyes in 2011 and is headquartered in Concord, MA.